Streetbeat News

MURA

Mural Oncology plc

https://www.muraloncology.com

Industry

Biotechnology

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Open

3.46

Mkt cap

57M

Volume

42K

High

3.49

P/E Ratio

-0.33

52-wk high

6.25

Low

3.35

Div yield

N/A

52-wk low

2.88

Mural Oncology (NASDAQ:MURA) reported a Q2 2024 GAAP EPS of $(1.86), an improvement from $(3.01) per share in the same period last year, representing a 38.21% increase.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:21 am

Rodman & Renshaw initiates coverage on Mural Oncology (NASDAQ:MURA) with a Buy rating and sets a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 4:47 pm

Mural Oncology shared data from the ARTISTRY-3 trial, which evaluated the effects of less frequent intravenous dosing of Nemvaleukin Alfa. The trial demonstrated pharmacodynamic proof of mechanism and showed that Nemvaleukin was generally well-tolerated at all doses tested.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:30 pm

Mural Oncology presented preclinical data for its IL-18 and IL-12 programs at the 2024 American Association For Cancer Research Annual Meeting, indicating progress in their development. The company expects to nominate candidates for each program later this year. The data showed that their IL-18 variant, with enhanced half-life and resistance, demonstrated durable immunological effects. Additionally, their engineered IL-12 approach aims to reduce toxicity while maintaining efficacy.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:01 pm

Mural Oncology's stock price increased following Morgan Stanley's initiation of coverage with an Overweight rating and a $13 price target.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 11:57 am

Morgan Stanley analyst Judah Frommer has initiated coverage on Mural Oncology (NASDAQ:MURA) with an Overweight rating and set a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 10:39 am

Mural Oncology (NASDAQ:MURA) reported a Q4 EPS loss of $(3.57), a 22.68% increase in losses compared to $(2.91) per share from the same period last year. The company also reported a cash balance of $270.9M.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:18 am

Westfield Capital Management has disclosed an 11.9% passive stake in Mural Oncology, as reported in a 13G filing.

Portfolio Pulse from Charles Gross

January 10, 2024 | 11:14 am

Mural Oncology has announced improvements to its late-stage clinical trials and plans to nominate development candidates for its engineered therapies targeting Interleukin-18 and Interleukin-12 in 2024. The company also projects its cash runway to extend into the fourth quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:20 pm

Applied UV, Inc. (AUVI) shares soared by approximately 96% in pre-market trading following the release of their third-quarter results, which showed a reduced loss per share and a significant increase in sales compared to the previous year. The company also reaffirmed its revenue guidance for 2023. Other stocks experienced movement in pre-market trading, with notable gainers including Bruush Oral Care Inc. (BRSH), Blue Star Foods Corp. (BSFC), and Yoshiharu Global Co. (YOSH), among others. Conversely, several companies saw their shares decline, such as Safe and Green Development Corporation (SGD), WANG & LEE GROUP, Inc. (WLGS), and Mural Oncology plc (MURA).

Portfolio Pulse from Lisa Levin

November 20, 2023 | 1:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.